{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T13:56:27Z","timestamp":1794578187393,"version":"4.9.1"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T00:00:00Z","timestamp":1733356800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T00:00:00Z","timestamp":1733356800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Genom Data"],"DOI":"10.1186\/s12863-024-01286-y","type":"journal-article","created":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T10:18:46Z","timestamp":1733393926000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Pharmacogenomic insights into tuberculosis treatment shows the NAT2 genetic variants linked to hepatotoxicity risk: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"25","author":[{"given":"Rashmi","family":"Mahajan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anuj Kumar","family":"Tyagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,5]]},"reference":[{"key":"1286_CR1","doi-asserted-by":"publisher","first-page":"65","DOI":"10.3389\/fcimb.2020.00065","volume":"10","author":"MG Moule","year":"2020","unstructured":"Moule MG, Cirillo JD. Mycobacterium tuberculosis dissemination plays a critical role in pathogenesis. Front Cell Infect Microbiol. 2020;10:65.","journal-title":"Front Cell Infect Microbiol"},{"key":"1286_CR2","unstructured":"Global tuberculosis report 2023. WHO. License no. CC BY-NC-SA 3.0 IGO. Geneva: World Health Organization."},{"key":"1286_CR3","first-page":"474","volume":"48","author":"N Pourmohamadi","year":"2023","unstructured":"Pourmohamadi N. Pour Abdollah Toutkaboni M, Hayati Roodbari N, Tabarsi P, Baniasadi S. Association of cytochrome P450 2E1 and N-Acetyltransferase 2 genotypes with serum isoniazid level and anti-tuberculosis drug-induced hepatotoxicity: A cross-sectional study. Iran J Med Sci. 2023;48:474\u201383.","journal-title":"Iran J Med Sci."},{"key":"1286_CR4","doi-asserted-by":"publisher","first-page":"118","DOI":"10.4103\/ijmr.IJMR_2013_15","volume":"145","author":"AK Hemanth Kumar","year":"2017","unstructured":"Hemanth Kumar AK, Ramesh K, Kannan T, Sudha V, Haribabu H, Lavanya J, et al. N-acetyltransferase gene polymorphisms & plasma isoniazid concentrations in patients with tuberculosis. Indian J Med Res. 2017;145:118\u201323.","journal-title":"Indian J Med Res"},{"key":"1286_CR5","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.598","volume":"8","author":"JN Pillaye","year":"2020","unstructured":"Pillaye JN, Marakalala MJ, Khumalo N, Spearman W, Ndlovu H. Mechanistic insights into antiretroviral drug-induced liver injury. Pharmacol Res Perspect. 2020;8: e00598.","journal-title":"Pharmacol Res Perspect"},{"key":"1286_CR6","doi-asserted-by":"publisher","first-page":"7164","DOI":"10.1128\/AAC.03258-14","volume":"58","author":"A Requena-M\u00e9ndez","year":"2014","unstructured":"Requena-M\u00e9ndez A, Davies G, Waterhouse D, Ardrey A, Jave O, L\u00f3pez-Romero SL, et al. Effects of dosage, comorbidities, and food on isoniazid pharmacokinetics in Peruvian tuberculosis patients. Antimicrob Agents Chemother. 2014;58:7164\u201370.","journal-title":"Antimicrob Agents Chemother"},{"key":"1286_CR7","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1186\/s12890-023-02646-7","volume":"23","author":"WJ Seo","year":"2023","unstructured":"Seo WJ, Koo HK, Kang JY, Kang J, Park SH, Kang HK, et al. Risk adjustment model for tuberculosis compared to non-tuberculosis mycobacterium or latent tuberculosis infection: center for personalized precision medicine of tuberculosis (cPMTb) cohort database. BMC Pulm Med. 2023;23:471.","journal-title":"BMC Pulm Med"},{"key":"1286_CR8","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1007\/s00228-022-03362-7","volume":"78","author":"L Thomas","year":"2022","unstructured":"Thomas L, Raju AP, Chaithra MSS, Varma M, Saravu K, et al. Influence of N-acetyltransferase 2 (NAT2) genotype\/single nucleotide polymorphisms on clearance of isoniazid in tuberculosis patients: a systematic review of population pharmacokinetic models. Eur J Clin Pharmacol. 2022;78:1535\u201353.","journal-title":"Eur J Clin Pharmacol"},{"key":"1286_CR9","doi-asserted-by":"publisher","first-page":"1332752","DOI":"10.3389\/fphar.2024.1332752","volume":"15","author":"V Ulanova","year":"2024","unstructured":"Ulanova V, Kivrane A, Viksna A, Pahirko L, Freimane L, Sadovska D, et al. Effect of NAT2, GSTM1 and CYP2E1 genetic polymorphisms on plasma concentration of isoniazid and its metabolites in patients with tuberculosis, and the assessment of exposure-response relationships. Front Pharmacol. 2024;15:1332752.","journal-title":"Front Pharmacol"},{"key":"1286_CR10","doi-asserted-by":"crossref","unstructured":"Figueiredo Teixeira RL de, Pires Lopes MQ, Noel P, Rezende A. Tuberculosis pharmacogenetics: state of the art. In: Mahboub B, editor. Tuberculosis - Current Issues in Diagnosis and Management. InTech; 2013.","DOI":"10.5772\/54984"},{"key":"1286_CR11","doi-asserted-by":"publisher","first-page":"11438","DOI":"10.1038\/s41598-023-38716-3","volume":"13","author":"T Sileshi","year":"2023","unstructured":"Sileshi T, Telele NF, Burkley V, Makonnen E, Aklillu E. Correlation of N-acetyltransferase 2 genotype and acetylation status with plasma isoniazid concentration and its metabolic ratio in ethiopian tuberculosis patients. Sci Rep. 2023;13:11438.","journal-title":"Sci Rep"},{"key":"1286_CR12","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1111\/j.1365-2044.1992.tb03256.x","volume":"47","author":"A Gurnani","year":"1992","unstructured":"Gurnani A, Chawla R, Kundra P, Bhattacharya A. Acute isoniazid poisoning. Anaesthesia. 1992;47:781\u20133.","journal-title":"Anaesthesia"},{"key":"1286_CR13","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/j.apsb.2016.07.014","volume":"6","author":"P Wang","year":"2016","unstructured":"Wang P, Pradhan K, Zhong X-B, Ma X. Isoniazid metabolism and hepatotoxicity. Acta Pharm Sin B. 2016;6:384\u201392.","journal-title":"Acta Pharm Sin B"},{"key":"1286_CR14","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1097\/FPC.0000000000000232","volume":"26","author":"DJ Klein","year":"2016","unstructured":"Klein DJ, Boukouvala S, McDonagh EM, Shuldiner SR, Laurieri N, Thorn CF, et al. PharmGKB summary: isoniazid pathway, pharmacokinetics. Pharmacogenet Genomics. 2016;26:436\u201344.","journal-title":"Pharmacogenet Genomics"},{"key":"1286_CR15","doi-asserted-by":"publisher","first-page":"1083780","DOI":"10.3389\/fimmu.2022.1083780","volume":"13","author":"J Gong","year":"2022","unstructured":"Gong J, Tu W, Liu J, Tian D. Hepatocytes: A key role in liver inflammation. Front Immunol. 2022;13:1083780.","journal-title":"Front Immunol"},{"key":"1286_CR16","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.taap.2008.01.002","volume":"229","author":"S Tafazoli","year":"2008","unstructured":"Tafazoli S, Mashregi M, O\u2019Brien PJ. Role of hydrazine in isoniazid-induced hepatotoxicity in a hepatocyte inflammation model. Toxicol Appl Pharmacol. 2008;229:94\u2013101.","journal-title":"Toxicol Appl Pharmacol"},{"key":"1286_CR17","doi-asserted-by":"publisher","DOI":"10.1002\/mgg3.1987","volume":"10","author":"L Jaramillo-Valverde","year":"2022","unstructured":"Jaramillo-Valverde L, Levano KS, Tarazona DD, Capristano S, Zegarra-Chapo\u00f1an R, Sanchez C, et al. NAT2 and CYP2E1 polymorphisms and antituberculosis drug-induced hepatotoxicity in Peruvian patients. Mol Genet Genomic Med. 2022;10: e1987.","journal-title":"Mol Genet Genomic Med"},{"key":"1286_CR18","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1590\/S0074-02762011000600011","volume":"106","author":"RL Teixeira","year":"2011","unstructured":"Teixeira RL, Morato RG, Cabello PH, Muniz LMK, Moreira AS, Kritski AL, et al. Genetic polymorphisms of NAT2, CYP2E1 and GST enzymes and the occurrence of antituberculosis drug-induced hepatitis in Brazilian TB patients. Mem Inst Oswaldo Cruz. 2011;106:716\u201324.","journal-title":"Mem Inst Oswaldo Cruz."},{"key":"1286_CR19","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.tube.2014.02.003","volume":"94","author":"N Singla","year":"2014","unstructured":"Singla N, Gupta D, Birbian N, Singh J. Association of NAT2, GST and CYP2E1 polymorphisms and anti-tuberculosis drug-induced hepatotoxicity. Tuberculosis (Edinb). 2014;94:293\u20138.","journal-title":"Tuberculosis (Edinb)"},{"key":"1286_CR20","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1007\/s00228-014-1703-0","volume":"70","author":"CS Ng","year":"2014","unstructured":"Ng CS, Hasnat A, Al Maruf A, Ahmed MU, Pirmohamed M, Day CP, et al. N-acetyltransferase 2 (NAT2) genotype as a risk factor for development of drug-induced liver injury relating to antituberculosis drug treatment in a mixed-ethnicity patient group. Eur J Clin Pharmacol. 2014;70:1079\u201386.","journal-title":"Eur J Clin Pharmacol"},{"key":"1286_CR21","doi-asserted-by":"publisher","first-page":"499","DOI":"10.5588\/ijtld.12.0645","volume":"17","author":"NP Santos","year":"2013","unstructured":"Santos NP, Callegari-Jacques SM, Ribeiro Dos Santos AK, Silva CA, Vallinoto AC, Fernandes DC, et al. N-acetyl transferase 2 and cytochrome P450 2E1 genes and isoniazid-induced hepatotoxicity in Brazilian patients. Int J Tuberc Lung Dis. 2013;17:499\u2013504.","journal-title":"Int J Tuberc Lung Dis."},{"key":"1286_CR22","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1097\/FPC.0b013e32835e95e1","volume":"23","author":"H-T Ho","year":"2013","unstructured":"Ho H-T, Wang T-H, Hsiong C-H, Perng W-C, Wang N-C, Huang T-Y, et al. The NAT2 tag SNP rs1495741 correlates with the susceptibility of antituberculosis drug-induced hepatotoxicity. Pharmacogenet Genomics. 2013;23:200\u20137.","journal-title":"Pharmacogenet Genomics"},{"key":"1286_CR23","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1111\/jgh.12194","volume":"28","author":"VH Gupta","year":"2013","unstructured":"Gupta VH, Amarapurkar DN, Singh M, Sasi P, Joshi JM, Baijal R, et al. Association of N-acetyltransferase 2 and cytochrome P450 2E1 gene polymorphisms with antituberculosis drug-induced hepatotoxicity in Western India. J Gastroenterol Hepatol. 2013;28:1368\u201374.","journal-title":"J Gastroenterol Hepatol"},{"key":"1286_CR24","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/s12072-011-9309-4","volume":"6","author":"SV Rana","year":"2012","unstructured":"Rana SV, Ola RP, Sharma SK, Arora SK, Sinha SK, Pandhi P, et al. Comparison between acetylator phenotype and genotype polymorphism of N-acetyltransferase-2 in tuberculosis patients. Hepatol Int. 2012;6:397\u2013402.","journal-title":"Hepatol Int"},{"key":"1286_CR25","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.patbio.2011.07.001","volume":"60","author":"L Ben Mahmoud","year":"2012","unstructured":"Ben Mahmoud L, Ghozzi H, Kamoun A, Hakim A, Hachicha H, Hammami S, et al. Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatotoxicity in Tunisian patients with tuberculosis. Pathol Biol. 2012;60:324\u201330.","journal-title":"Pathol Biol"},{"key":"1286_CR26","first-page":"803","volume":"25","author":"T Sotsuka","year":"2011","unstructured":"Sotsuka T, Sasaki Y, Hirai S, Yamagishi F, Ueno K. Association of isoniazid-metabolizing enzyme genotypes and isoniazid-induced hepatotoxicity in tuberculosis patients. In Vivo. 2011;25:803\u201312.","journal-title":"In Vivo"},{"key":"1286_CR27","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1111\/j.1440-1746.2010.06355.x","volume":"26","author":"PD Bose","year":"2011","unstructured":"Bose PD, Sarma MP, Medhi S, Das BC, Husain SA, Kar P. Role of polymorphic N-acetyl transferase 2 and cytochrome P4502E1 gene in antituberculosis treatment-induced hepatitis. J Gastroenterol Hepatol. 2011;26:312\u20138.","journal-title":"J Gastroenterol Hepatol"},{"key":"1286_CR28","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.2217\/pgs.09.66","volume":"10","author":"S Yamada","year":"2009","unstructured":"Yamada S, Tang M, Richardson K, Halaschek-Wiener J, Chan M, Cook VJ, et al. Genetic variations of NAT2 and CYP2E1 and isoniazid hepatotoxicity in a diverse population. Pharmacogenomics. 2009;10:1433\u201345.","journal-title":"Pharmacogenomics"},{"key":"1286_CR29","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1007\/s00228-008-0484-8","volume":"64","author":"LG Possuelo","year":"2008","unstructured":"Possuelo LG, Castelan JA, de Brito TC, Ribeiro AW, Cafrune PI, Picon PD, et al. Association of slow N-acetyltransferase 2 profile and anti-TB drug-induced hepatotoxicity in patients from Southern Brazil. Eur J Clin Pharmacol. 2008;64:673\u201381.","journal-title":"Eur J Clin Pharmacol"},{"key":"1286_CR30","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.tube.2007.05.012","volume":"87","author":"H-J Cho","year":"2007","unstructured":"Cho H-J, Koh W-J, Ryu Y-J, Ki C-S, Nam M-H, Kim J-W, et al. Genetic polymorphisms of NAT2 and CYP2E1 associated with antituberculosis drug-induced hepatotoxicity in Korean patients with pulmonary tuberculosis. Tuberculosis (Edinb). 2007;87:551\u20136.","journal-title":"Tuberculosis (Edinb)"},{"key":"1286_CR31","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/s00228-006-0111-5","volume":"62","author":"N Vuilleumier","year":"2006","unstructured":"Vuilleumier N, Rossier MF, Chiappe A, Degoumois F, Dayer P, Mermillod B, et al. CYP2E1 genotype and isoniazid-induced hepatotoxicity in patients treated for latent tuberculosis. Eur J Clin Pharmacol. 2006;62:423\u20139.","journal-title":"Eur J Clin Pharmacol"},{"key":"1286_CR32","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1053\/jhep.2002.32102","volume":"35","author":"YS Huang","year":"2002","unstructured":"Huang YS, Chern HD, Su WJ, Wu JC, Lai SL, Yang SY, et al. Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis. Hepatology. 2002;35:883\u20139.","journal-title":"Hepatology"},{"key":"1286_CR33","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1080\/17512433.2024.2311314","volume":"17","author":"L Thomas","year":"2024","unstructured":"Thomas L, Raju AP, Chaithra S, Kulavalli S, Varma M, Sv CS, et al. Influence of N-acetyltransferase 2 polymorphisms and clinical variables on liver function profile of tuberculosis patients. Expert Rev Clin Pharmacol. 2024;17:263\u201374.","journal-title":"Expert Rev Clin Pharmacol"},{"key":"1286_CR34","doi-asserted-by":"crossref","unstructured":"Cavaco MJ, Alcobia C, Oliveiros B, Mesquita LA, Carvalho A, Matos F, et al. Clinical and Genetic Risk Factors for Drug-Induced Liver Injury Associated with Anti-Tuberculosis Treatment-A Study from Patients of Portuguese Health Centers. J Pers Med. 2022;12:790.","DOI":"10.3390\/jpm12050790"},{"key":"1286_CR35","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.aohep.2019.09.008","volume":"19","author":"C Araujo-Mariz","year":"2020","unstructured":"Araujo-Mariz C, Milit\u00e3o de Albuquerque MFP, Lopes EP, Ximenes RAA, Lacerda HR, Miranda-Filho DB, et al. Hepatotoxicity during TB treatment in people with HIV\/AIDS related to NAT2 polymorphisms in Pernambuco. Northeast Brazil Ann Hepatol. 2020;19:153\u201360.","journal-title":"Northeast Brazil. Ann Hepatol."},{"key":"1286_CR36","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1038\/tpj.2016.26","volume":"17","author":"N Ben Fredj","year":"2017","unstructured":"Ben Fredj N, Gam R, Kerkni E, Chaabane A, Chadly Z, Boughattas N, et al. Risk factors of isoniazid-induced hepatotoxicity in Tunisian tuberculosis patients. Pharmacogenomics J. 2017;17:372\u20137.","journal-title":"Pharmacogenomics J"},{"key":"1286_CR37","doi-asserted-by":"publisher","first-page":"16014","DOI":"10.1038\/hgv.2016.14","volume":"3","author":"T Mushiroda","year":"2016","unstructured":"Mushiroda T, Yanai H, Yoshiyama T, Sasaki Y, Okumura M, Ogata H, et al. Development of a prediction system for anti-tuberculosis drug-induced liver injury in Japanese patients. Hum Gen Variation. 2016;3:16014.","journal-title":"Hum Gen Variation"},{"key":"1286_CR38","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0085905","volume":"9","author":"Y Xiang","year":"2014","unstructured":"Xiang Y, Ma L, Wu W, Liu W, Li Y, Zhu X, et al. The incidence of liver injury in Uyghur patients treated for TB in Xinjiang Uyghur autonomous region, China, and its association with hepatic enzyme polymorphisms NAT2, CYP2E1, GSTM1 and GSTT1. PLoS ONE. 2014;9: e85905.","journal-title":"PLoS ONE"},{"key":"1286_CR39","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/S1665-2681(19)31446-2","volume":"11","author":"X Lv","year":"2012","unstructured":"Lv X, Tang S, Xia Y, Zhang Y, Wu S, Yang Z, et al. NAT2 genetic polymorphisms and anti-tuberculosis drug-induced hepatotoxicity in Chinese community population. Ann Hepatol. 2012;11:700\u20137.","journal-title":"Ann Hepatol"},{"key":"1286_CR40","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.5588\/ijtld.10.0648","volume":"15","author":"V Leiro-Fernandez","year":"2011","unstructured":"Leiro-Fernandez V, Valverde D, V\u00e1zquez-Gallardo R, Botana-Rial M, Constenla L, Ag\u00fandez JA, et al. N-acetyltransferase 2 polymorphisms and risk of anti-tuberculosis drug-induced hepatotoxicity in Caucasians. Int J Tuberc Lung Dis. 2011;15:1403\u20138.","journal-title":"Int J Tuberc Lung Dis"},{"key":"1286_CR41","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.2217\/pgs.15.144","volume":"16","author":"J Shi","year":"2015","unstructured":"Shi J, Xie M, Wang J, Xu Y, Liu X. Susceptibility of N-acetyltransferase 2 slow acetylators to antituberculosis drug-induced liver injury: a meta-analysis. Pharmacogenomics. 2015;16:2083\u201397.","journal-title":"Pharmacogenomics"},{"key":"1286_CR42","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1186\/s12889-015-1614-8","volume":"15","author":"D Lukoye","year":"2015","unstructured":"Lukoye D, Ssengooba W, Musisi K, Kasule GW, Cobelens FGJ, Joloba M, et al. Variation and risk factors of drug resistant tuberculosis in sub-Saharan Africa: a systematic review and meta-analysis. BMC Public Health. 2015;15:291.","journal-title":"BMC Public Health"},{"key":"1286_CR43","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1097\/FPC.0000000000000339","volume":"28","author":"S Suvichapanich","year":"2018","unstructured":"Suvichapanich S, Fukunaga K, Zahroh H, Mushiroda T, Mahasirimongkol S, Toyo-Oka L, et al. NAT2 ultra-slow acetylator and risk of anti-tuberculosis drug-induced liver injury: a genotype-based meta-analysis. Pharmacogenet Genomics. 2018;28:167\u201376.","journal-title":"Pharmacogenet Genomics"},{"key":"1286_CR44","doi-asserted-by":"publisher","first-page":"2747","DOI":"10.1111\/bcp.13722","volume":"84","author":"M Zhang","year":"2018","unstructured":"Zhang M, Wang S, Wilffert B, Tong R, van Soolingen D, van den Hof S, et al. The association between the NAT2 genetic polymorphisms and risk of DILI during anti-TB treatment: a systematic review and meta-analysis. Br J Clin Pharmacol. 2018;84:2747\u201360.","journal-title":"Br J Clin Pharmacol"},{"key":"1286_CR45","doi-asserted-by":"crossref","unstructured":"Khan S, Mandal RK, Elasbali AM, Dar SA, Jawed A, Wahid M, et al. Pharmacogenetic association between NAT2 gene polymorphisms and isoniazid induced hepatotoxicity: trial sequence meta-analysis as evidence. Biosci Rep. 2019;39:BSR20180845.","DOI":"10.1042\/BSR20180845"},{"key":"1286_CR46","doi-asserted-by":"publisher","first-page":"293","DOI":"10.5588\/ijtld.18.0324","volume":"23","author":"M Richardson","year":"2019","unstructured":"Richardson M, Kirkham J, Dwan K, Sloan DJ, Davies G, Jorgensen AL. NAT2 variants and toxicity related to anti-tuberculosis agents: a systematic review and meta-analysis. Int J Tuberc Lung Dis. 2019;23:293\u2013305.","journal-title":"Int J Tuberc Lung Dis"},{"key":"1286_CR47","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1080\/17512433.2023.2196401","volume":"16","author":"J Li","year":"2023","unstructured":"Li J, Cai X, Chen Y, Wang C, Jiao Z. Parametric population pharmacokinetics of isoniazid: a systematic review. Expert Rev Clin Pharmacol. 2023;16:467\u201389.","journal-title":"Expert Rev Clin Pharmacol"},{"key":"1286_CR48","doi-asserted-by":"crossref","unstructured":"Gafar F, Wasmann RE, McIlleron HM, Aarnoutse RE, Schaaf HS, Marais BJ, et al. Global estimates and determinants of antituberculosis drug pharmacokinetics in children and adolescents: a systematic review and individual patient data meta-analysis. Eur Respir J. 2023;61.","DOI":"10.1183\/13993003.01596-2022"},{"key":"1286_CR49","doi-asserted-by":"publisher","first-page":"e027940","DOI":"10.1136\/bmjopen-2018-027940","volume":"9","author":"S Yang","year":"2019","unstructured":"Yang S, Hwang SJ, Park JY, Chung EK, Lee JI. Association of genetic polymorphisms of CYP2E1, NAT2, GST and SLCO1B1 with the risk of anti-tuberculosis drug-induced liver injury: a systematic review and meta-analysis. BMJ Open. 2019;9:e027940.","journal-title":"BMJ Open"},{"key":"1286_CR50","doi-asserted-by":"publisher","first-page":"123","DOI":"10.2174\/1875692118666210928170636","volume":"18","author":"NFM Noor","year":"2021","unstructured":"Noor NFM, Kek TL, Zim MAM, Bakar ZA, Zakaria NI, Lailanor MI, et al. Association of N-acetyltransferase-2 Polymorphism with AntituberculosisInduced Hepatotoxicity: A Meta-analysis. Curr Pharmacogenomics Person Med. 2021;18:123\u201332.","journal-title":"Curr Pharmacogenomics Person Med"}],"container-title":["BMC Genomic Data"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12863-024-01286-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12863-024-01286-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12863-024-01286-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T11:04:22Z","timestamp":1733396662000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgenet.biomedcentral.com\/articles\/10.1186\/s12863-024-01286-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,5]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1286"],"URL":"https:\/\/doi.org\/10.1186\/s12863-024-01286-y","relation":{},"ISSN":["2730-6844"],"issn-type":[{"value":"2730-6844","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,5]]},"assertion":[{"value":"3 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"103"}}